greenhouse technology

Mike Sassano: Increasing Potency with Greenhouse Technology

Michael Sassano is the CEO and founder of Solaris Farms, one of three large greenhouse cannabis cultivators in Nevada. We recently checked in with Mike for an interview covering Nevada’s adult-use market, the latest greenhouse technology advances, and his advice for cannabis cultivators and other industry operators.

Scroll down to read through Mike’s advice, anecdotes, and predictions for the future of cannabis.


Ganjapreneur: What was your career that led to founding a cannabis farm, and what originally sparked the idea that led to Solaris Farms?

Mike Sassano: I have had many experiences based on extensive travel and a private equity career. I did extremely well as the number one arbitrage trader at CIBC and used that skill and resources to be an avid tech and real estate investor in the mid/late ’90s. I saw many cycles up and down until the “Big One” of 2008. Cannabis held a great personal appeal because it was not reliant on big banks and encompassed real estate development, sustainable resources, and technology all in one. But the idea of going industrial didn’t come to me until early 2015 when I traveled the world learning all the best techniques of growing from normal food farmers. By 2016 Solaris Farms was being built and by 2017 our genetics were being developed. The ride since has been all-in on cannabis.

What are the benefits for cannabis to greenhouse cultivation, and what about Solaris’ greenhouse technology makes it specialized for growing cannabis?

Let me count the ways! First: We are a hybrid greenhouse. There is a big distinction. In order to control the environment like an indoor facility, you must think out of the box and look at the latest technological marvels in hybrid greenhouses. Although Solaris was designed 3+ years ago, our next generation is much more efficient and in control. Second: Cost savings. I do not believe that indoor on any scale, besides large scale multi-leveled LED projects, will be able to keep up with the fractional costs of hybrid-greenhouse. Third: The ability to control all aspects of the environment allows for higher, more sensitive genetics to be cultivated. Fourth: Cost to build is significantly lower and only outdoor can beat the price, but not the quality. Fifth: Contamination prevention is superior to normal greenhouses and is extremely key as more and more states and countries adopt strict rules to protect the consumers. Sixth: Data is easier to accumulate and analyze since the environment is more stabilized.

How much R&D was required to get your hybrid greenhouse technology up and running? Could you elaborate a bit on your development process and explain the incoming improvements?

Back in 2015, I had already made the decision to make a large scale greenhouse. At that time, 350,000 sq ft was the biggest I had heard of. But the trick was to control the environment of Nevada. I traveled literally around the world, North to South, cold to hot, South America to Asia to the deserts of Kuwait, visiting the largest agricultural food producers and learning. The fluctuating heat and cold of the desert were more extreme in Kuwait than Vegas, so Solaris was born from a similar design. I also cribbed some details from Cargill, like a central spline and other details. The next phase is 300,000 sq ft to max out our potential. Since then I have designed other greenhouses. The phase after that will be glass and fully-enclosed like the more modern greenhouses that are being made. With 24’ peaks, the airflow and air contamination equipment will be superior. Post-harvest automation can best be described as one of those machines that laundry mats have, whereby the plants are hung and transported to dry rooms then to trim rooms in the most efficient manner with the least disruption and handling. I spend most of my time working on post-harvest automation and de-contamination equipment choices.

Could you describe the response to Solaris Farms’ products from consumers and retailers? Have you had a particularly popular strain/offering?

We have four high producing strains that have been testing from 25% to 30%+ THC, over 32% cannabinoids and at least 8-12mg’s of the two top dominant terpenes: Las Vegas Kush, Fire Chem, White Cookies, and LA Afghan. Then we have 4 strains producing slightly less but still 23-28% THC, over 30% Cannabinoids and similar 7-11mg’s of top dominant terpenes: 91 Chem Hawaiian Sativa, 91 Chem, HP13, and old fashioned Moonshine. Every dispensary knows us in Vegas and our product is sold as the test results come in. I throw a party every month or two in order to meet everyone, show appreciation, and celebrate our industry. We have an open door tour policy; as long as you haven’t been to another grow that day, you can come in and we will show you how we do everything. Our board room has a viewing area that people enjoy coming to and meeting with us. We have almost zero turnovers and the industry knows we create a great environment for everyone and our plants.

How many employees work at Solaris Farms, and which qualities do you think are most important for being part of a successful team in the cannabis space?

Solaris Farms has 23 full-time positions and 18 part-time positions. Solaris prides itself on well-over 50% diversity in ethnicity, race, and gender. We believe diversity is one of the keys to our success. We create an environment that fosters growth and has one of the lowest turnover ratios in the industry; only one in the past year. Each manager carries a future vision and is chosen because they are leaders, can perform, and know-how to create a successful environment.

Are there any major misconceptions you have to confront about owning/operating a cannabis farm?

The most abused perception, which causes our industry to be taken advantage of, is that people believe that we are all billionaires or hundred-millionaires and that profits are rolling in the doors like crazy. No, profit and wealth in this industry take hard work and precision. And those who gained it too easily may not be the ones you want to emulate. The best is yet to come. And this is much better than working for a living *laughs*

Where do you hope to see Solaris Farms in the next five years? And how about 20 years down the road?

Solaris was built to last, but inevitably we also must expand. Keeping a top 10 position in Nevada should be consistent. Expanding to Europe is in the works. That will be very challenging. And hopefully, an East coast hub will come together in 5 years. We hope in that time to have our tinctures and gelcaps in most legal states. In 20 years, I hope to be sitting on the grow in Europe eating cheese and drinking wine watching the plants grow since I will be 69:)

What can cannabis cultivators do to expand their brand’s reach and footprint in the industry?

The simplest and lowest-cost way is to bring your best few products to other states by renting space at other facilities. All it requires is sourcing the THC, some equipment and packaging, plus a manager and salesperson. I’m doing it, so why shouldn’t everyone?

What is the most common mistake you’ve seen other cannabis brands/entrepreneurs make?

There are many people that think they are better than everyone and haven’t learned to make friends and to help people. This creates the “island unto themselves” attitude. I help anyone who reaches out to me. I will give expensive advice for free. And guess what? When I need help, people are there for me doing the same. We all need help, so check the attitude at the door. One thing is certain, profitability is elusive as you grow and we should all be humble.

Are you planning to expand into any other state markets? Why so, or why not?

Just by branding. I believe that in the future there are no barriers to states and countries. I also believe that worldwide distribution channels will be open. All you need is brand recognition now and a few distribution points.

What advice would you offer to entrepreneurs and/or farmers who are considering pursuing a cannabis cultivation license?

In order to compete in today’s market, it takes 110% dedication and sacrifices, plus a heck of a lot of money that wasn’t needed 10 years ago. Don’t underestimate delays, costs, and lower than expected sales prices. As good as you think you are, cannabis is humbling to everyone. Extend your visions past the idea of greatness and think of all the competition and how to really beat them. But, more importantly, survive with them in the world. Be cautious and not frivolous. And then enjoy the ride…


Thanks, Mike, for taking the time to answer our questions! To learn more about Solaris Farms and greenhouse technology, you can visit the company website at SolarisFarms.org or reach out on Instagram @solarisfarms.

End


Former VA Secretary: “Time Is Now” to Research Medical Cannabis

In an interview with Task & Purpose, former Veterans Affairs Secretary David Shulkin said the “time is now” to research medical cannabis, adding that the federal “hoops” researchers have to jump through make it “too difficult” for most to study the plant.

“I believe that the VA should be involved in research on anything that could potentially help veterans and improve their health and well-being.” – Shulkin, to Task & Purpose

Shulkin said he believes that medical marijuana access could help stem suicides by military men and women because the suicides are often linked to chronic pain, depression, and substance abuse. He said that he believes “properly prescribed” medical cannabis “may have some real benefits in anxiety improvement, in pain management, and potentially, in the issue of substance abuse.”

“And therefore, I believe it’s extremely appropriate for VA to be researching and developing therapies that can help veterans, particularly in areas where we don’t have enough good therapies or answers,” he said in the interview.

The former VA secretary said he did see a “way forward” for veterans to access medical cannabis – namely federal legislative solutions which could streamline and clarify the rules and regulations for medical cannabis research.

Shulkin said he had “no indication” that President Donald Trump “wouldn’t be supportive” of changes to allow the VA to study medical cannabis.

Shulkin was appointed to the role in 2015 by President Barack Obama and served until 2017.

End


cbd company

United Natural Products Alliance Adds First CBD Company

The United Natural Products Alliance (UNPA) has outlined its new policy on CBD for both new and existing association members. The policy does not allow associated companies to sell synthetic cannabinoids or CBD products used for inhalation, advertising must comply with the Federal Trade Commission and Food Safety Modernization Act rules, and the business must be state-approved.

“While efforts at the state and federal level to clarify the legal status of hemp extract and cannabinoid products continue, UNPA believes it is in the interest of consumers, health professionals and relevant industries to establish a framework of practices and compliance standards for hemp extract/cannabinoid products.” – UNPA Hemp Extract/Cannabinoid New Member Policy Guidelines, October 2019

The association also announced its first hemp member – Colorado-based Mile High Labs. Fenella Keig, compliance officer for Mile High Labs, said the company was “thrilled” to be the first CBD company to join the UNPA.

“The Alliance is unparalleled in its expertise and commitment to the supplement industry,” Keig said in a statement. “We look forward to working with UNPA leadership and other member organizations to create awareness of CBD and other hemp-derived products.”

UNPA President Loren Israelsen said the association was “honored” to add Mile High Labs as an executive member, lauding the company’s “commitment to quality, science and research.”

According to the release, Mile High Labs purchased a 400,000-square-foot former pharmaceutical plant in Broomfield, Colorado in June for the production of tinctures, capsules, tablets, topicals, and gummies for private label customers. The facility is also an environment for CBD industry research and collaboration. The firm also operates in Ireland and New Zealand.

End


social-use

New Mexico Officials Mulling ‘Consumption Areas’ for Cannabis Patients

The New Mexico Department of Health has proposed changes for the state’s medical cannabis program including reciprocity for patients from other states and guidelines for social-use “consumption areas,” according to NM Political Report. Under the rules, only current operators would be allowed to have consumption areas.

Under changes to the program approved during the 2019 session, consumption areas are “licensed premises approved by the department where cannabis may be consumed that complies with rules as established by the department.”

The health department rules would require those areas to be “located on the premises of licensed non-profit producers” and patients who used the areas would need to have a designated driver or “other lawful means of transportation” when leaving the site.

If approved by DOH Secretary Kathyleen Kunkel, it would mark the first time a state has approved social consumption for medical cannabis patients.

The reciprocity rule is not the same as recent changes to allow non-residents to obtain a New Mexico medical cannabis ID card but would allow out-of-state cardholders to purchase cannabis at New Mexico dispensaries. The non-resident patient plan has not come into fruition in the state as health officials have mostly refused to issue cards to non-residents since the law was signed by Gov. Michelle Lujan Grisham earlier this year. According to Department of Health figures, as of September, 12 out-of-state patients had been granted New Mexico patient ID cards.

Under the plan, an out-of-state patient would only need to provide identification and a medical cannabis card from their home state and could purchase up to about 8 ounces of dried cannabis flower or extracts in a rolling three-month period – consistent with what New Mexico patients can buy. Dispensaries would be required to enter the patient information in a DOH-run patient tracking system.

As of September, there were 77,168 medical cannabis patients in New Mexico.

End


cannabis in pharmacies

Canada’s Arthritis Society Wants Medical Cannabis In Pharmacies

The Arthritis Society believes that medical cannabis products in Canada should be sold in pharmacies and the federal government should lift its $1 per gram excise tax, the CBC reports. Jone Mitchell, the Arthritis Society’s executive director for Atlantic Canada, said the changes would put medical cannabis in line with other prescription medications.

“That will ensure that patients receive reliable education from trained health care professionals on the safe and effective use. And they also have an understanding of the other medications their patients may be taking.” — Mitchell, to the CBC

Some medical cannabis patients can get a license to cultivate their own cannabis at home but most have to have products mailed from a licensed supplier, which takes time and picking it up from a pharmacy is quicker and easier, Mitchell said.

The Green Party has included removing the excise tax on their party platform while the Conservative Party said they were reviewing the law, including tax policy, the report says.

In May 2018, Liberal members of parliament’s finance committee voted against an amendment to remove the excise tax, according to a Straight report. Pharmaceuticals containing synthetic cannabinoids with a DIN number – such as Sativex and Nabilone – are not subject to the tax.

During the debate on the proposal, MP Pierre Luc Dusseault of the New Democratic Party rallied against the tax, saying that 4,000 Canadians had written to members of Parliament to oppose the tax and that more than 260,000 people were using cannabis for medical purposes at that time.

In July, Health Canada reported that medical cannabis flower sales dropped 20 percent but concentrate sales rose 19.5 percent. A July survey by Abacus Data commissioned by Canadians for Fair Access to Medical Marijuana and the Arthritis Society and the Canadian Pharmacists Association found one in four Canadian patients said medical cannabis was harder to obtain post-legalization.

End


UK Regulators Ban Hemp-Infused Rum Ad Campaign

The United Kingdom Advertising Standards Authority has banned a $2.56 million ad campaign for a CBD-infused rum, ruling that claims made by the company were not allowed and alcohol ads cannot “link alcohol to illicit drugs.” 

The advertising for Dead Man’s Fingers hemp rum, a Cornish Rum Company brand, contained the phrase “it will quite literally blow your mind” which regulators said could “be understood as an indication that the product would change someone’s behavior or mood in the same way as cannabis.” The agency said they understood, though, that the phrase could “be understood as a term meaning to impress strongly” but its meaning was changed in context with cannabis. 

CBD is legal in the UK.

Regulators said the advertiser had a duty to “take particular care” to make sure they made no statements about CBD or hemp and the “product did not link alcohol to cannabis.” The three-ad campaign featured “a black background with neon green and pink text in a hand-painted style font,” skulls wearing cannabis leaf-adorned hats and smoking what “would be understood by consumers” to be a joint, the ruling says.

The ads also contained the word “munchies,” “chilled, man,” and “dealers wanted,” which regulators agreed with the Scottish government that they were all linked to cannabis.

“We concluded that because the ads featured imagery and wording associated with the illicit drug cannabis, the ads linked alcohol to illicit drugs and therefore breached the Code.” — ASA Ruling on the Cornish Rum Company, Ltd, Oct. 16, 2019 

The ASA ruled against the government claim that the ads appealed to youth, noting that the colors and imagery “gave each of the ads an adult tone.” Regulators did consider the language used “would be understood” by people under 18 but the ads didn’t breach the code.

The ASA said the ads “must not appear again in their current form.” According to Spirit Business, the campaign included out-of-home advertising, digital media, partnerships, events and a nationwide sampling campaign. 

End


Report: Canada’s Legalization Led to Increased Housing Prices

Cannabis legalization in Canada has led to an increase in housing prices and home shortages in some regions, according to an October 15 RE/MAX report. The report points to Smiths Falls, Ontario, home of Canopy Growth, a cannabis firm that employs 1,300 people, as an example of how the cannabis industry is affecting home prices and inventory.

In the Rideau-St. Lawrence region — which encompasses Smiths Falls — house prices are up 10.5 percent and home sales rose by 27.1 percent year-over-year, the report says. In Atlantic Canada, home of Breathing Green Solutions and Zenabis Global, “months of inventory” dropped from 45 in 2018 to just nine this year. 

In Windsor-Essex, home of Leamington, Ontario’s Aphria — which employs 1,000 people — average prices rose 9.10 percent and increased 7.82 percent year-over-year.  

In Western Canada, Calgary and Vancouver have more than 75 retail cannabis dispensaries, due to the provincial government rules that allow private businesses to open shops rather than just government-run shops, which have helped drive business’ real estate prices. Toronto, by comparison, has just six cannabis storefronts. 

The report notes that provinces with more cannabusinesses didn’t experience a negative impact on home values despite a survey by the company last year that found 65 percent of Canadians “would not like to live near retail cannabis stores.”

Christopher Alexander, RE/MAX executive vice-president of the Ontario and Atlantic region told CTV News that the “real story is that the cannabis industry is creating jobs and demand in the market.” 

“Whenever there’s job creation … it creates more demand in the marketplace and more often than not, (home) prices will start to rise.” — Alexander, to CTV News

In Vancouver, the report says, the 11 commercial stores are in mostly commercial areas and “not on the radar for most homebuyers.” In Winnipeg, “Baby Boomers and Gen X are most likely to ask about cannabis retail when choosing a neighborhood to buy a home.” In London, homebuyers are asking whether more commercial shops will open.

Most surveyed by RE/MAX, 72 percent, said living near a cannabis store was not a deciding factor in their move, while 44 percent said they would like to live near a legal dispensary. Two in 10 Canadians live near a retail dispensary, 25 percent said they would move if a retailer opened up in their neighborhood and 31 percent said a retail dispensary would deter them from buying a home.

End


wholesale cannabis

Brad Bogus: Simplifying Wholesale Cannabis Connections

Brad recently joined our podcast host TG Branfalt for an in-depth interview ranging from cannabis journalism — Brad worked for nine months as general manager for The Cannabist, the once-vibrant cannabis news outlet powered by The Denver Post — to the latest discoveries in cannabis classification, including a new emphasis on terpene content, unique cannabinoids such as CBG and THCV, and more! Brad also shares information about the latest wholesale cannabis offering from Confident Cannabis, Connect, which is capable of 3D-mapping cannabis purchase and distribution trends on a national scale.

Tune in to the interview via the media player below, or keep going to find a full transcript of this week’s Ganjapreneur.com Podcast episode!


Listen to the podcast:


Read the transcript:

Commercial: This episode of the Ganjapreneur Podcast is made possible by 420 friendly service providers in the Ganjapreneur Business Directory. If you need professional help with your business, from accounting to legal services to consulting, marketing, payment processing or insurance, visit ganjapreneur.com/businesses to find service providers who specialize in helping cannabis entrepreneurs like you. Visit the Ganjapreneur Business Directory today at ganjapreneur.com/businesses.

TG Branfalt: Hey there. I’m your host, TG Branfalt, and thank you for listening to the ganjapreneur.com podcast, where we try to bring you actionable information and normalize cannabis through the stories of ganjapreneurs, activists, and industry stakeholders. Today I’m joined by Brad Bogus, who’s the vice president of marketing for Confident Cannabis, makers of really, really cool software called Connect, and we’re going to talk a lot about that. He’s the former general manager of The Cannabist, he’s a fellow punk rock enthusiast. How are you doing this afternoon, man?

Brad Bogus: I am doing great, TG. Thanks for having me on, man.

TG Branfalt: Yeah, no. We’ve already had a chance to connect, look at Connect. No pun intended there. But before we talk about that man, tell me about you. How’d you end up in The Cannabist space, first with The Cannabist and now the vice president of marketing for Confident Cannabis?

Brad Bogus: Yeah. It’s really a weird and storied path because when you were talking about punk rock enthusiasm, I started off really essentially as a straight edger. When people that I went to college with know what I’m doing now, they tend to look at me with this head cocked to the side, like, “What the fuck are you doing? Cannabis?” I did a lot of my own stuff. I started two companies and ran them for collectively 11 years. I never really set out to be a business owner. I’ve always been an artist, but I tend to follow certain paths that interests me, and media and content, and all of the storytelling things that I’ve loved about art.

I found an application for it in the corporate world by making commercial video productions or online content media, and … I don’t know, after a while, I just got bored with it. I didn’t really have any intentions of doing that forever. I was just doing it, and I got to a point where I was like, “I’m done doing this. What do I want to do next?” It felt like the appropriate next step was to try getting a job. I hadn’t done that before, and to do it at a company that I actually really cared for because I had … When you’re an entrepreneur, you don’t really worry so much about, “I need to take any position that comes my way.” You’re like, “I can make this on my own if I need to, but I’m going to take the right position.”

I had talked with the mentor of mine. I wasn’t super excited about the Austin tech scene really, or the tech scene in general. That industry seemed busted and full of all sorts of issues, with sexism and diversity problems and just … it was stodgy and awful. Everything else around me seemed really uninteresting, and a mentor of mine was just like, “Just pick an industry that you actually think is really cool.” I had been using cannabis for a long time. I knew a lot about it. I just looked around and was like, “There’s not a lot of times in a lifetime that an entire industry starts from scratch, and can be done the right way,” which sounds a lot more interesting than trying to get an old industry to do good things.

That’s very hard. Anyway, that was what led me to look in the cannabis space. I found an opportunity at The Cannabist, knew a guy who worked at The Denver Post at a high level, that I had worked with previously in Austin. Got on the phone and went through the interview process and very quickly got hired on and recruited to Colorado.

TG Branfalt: What’d you do for The Cannabist as general manager? If you can just fill in our listeners on what happened to The Cannabist, which was really an excellent source for journalism in the space.

Brad Bogus: Yeah. The Cannabist was, I mean, only a nine month experience in my life, which in cannabis years, we talk about it being sort of like dog years. So extrapolate that, it feels like I was spending five years at The Cannabist. It was only nine months. That was an epic nine months. I joined The Cannabist right when it was at the peak of its reputation, and its reputation as the standard bearer for journalism in cannabis. It was launched by the Denver Post. It was the first major mainstream news organization that followed the SPJ code of ethics, and had the old school mastheads and they were now launching a space just dedicated to cannabis.

TG Branfalt: It was a big deal.

Brad Bogus: That’s a really big deal. Even made a bigger deal by the fact that The Denver Post previously came out against 64, which was the proposition that made cannabis recreationally legal in Colorado. Right? There’s a big shift in behavior in mainstream culture that occurred around The Cannabist being launched. It was launched by Ricardo Baca, who was the music editor of The Denver Post for 13 years prior, and just one of the most perfect personalities to be behind such a thing. It had been in place for about three years, maybe two and a half years by the time I joined on. It needed really its own team and its own leadership.

It wasn’t so much an extension of The Denver Post as it was a startup within the Denver Post. So the GM role of these types of projects tends to be a little bit more of sales role. I wasn’t really a salesperson, although I had done plenty of sales on my own in my own startups, but I brought content and marketing and branding and this understanding of digital media to the table that could really shift the way that The Cannabist operated, make it profitable, but also make it profitable without compromising its ethics. So that’s what they brought me on to do. The role of general manager, with me in place, was a little bit more like the CEO/publisher, except that we were within the Denver Post.

So the actual publisher of The Denver Post was the CEO and publisher on top of all of the properties that came out of the Denver Post. But if you took The Cannabist and made it its own standalone startup, I would have been the publisher, Ricardo, the editor in chief of our own publication. That’s the best way to think about it, right? That role. Generally, it’s a glorified sales director role within most media publications. But I didn’t run it that way, and our team really understood the value of The Cannabist brand in the industry, and so we did everything we could to elevate that. We swung for the fences on a number of different things like The Cannabist Awards that we held in Vegas or MJBiz, and it was really, really starting to soar.

But then the corporate overlords of media stepped in and ground their gears the way they do. These decisions are made by … Just to give you a sense of ownership here. The Cannabist is owned by the Denver post. The Denver Post is owned by the second largest media publisher in the United States called Digital First Media, which is owned by an even larger hedge fund called Alden Global, I think is the name of that group. What they do is they buy newspapers, they squeeze them down, they make sure … do a series of layoffs and cut expenses so they can generate profitability by removing expense. So a lot of these decisions are made by just evaluating spreadsheets. Right?

Unfortunately, no matter how good The Cannabist was doing for itself, no matter of the fact that it was actually profitable for the first time ever and was showing pretty large increases across the board for its numbers, it still wasn’t big enough to the overall spreadsheet, got crossed off, all of the salespeople were let go, they dissolved the role of the GM. Eventually dissolved the role of the editor in chief, and all of the dedicated journalists writing for The Cannabist, and it just became what it is now, which is a republisher of news on The Wire, and any news that comes out of The Denver Post that has anything to do with The Cannabist will be crossed … with cannabis in general, will be cross-posted there. But there’s no dedicated writing staff to it anymore.

TG Branfalt: No, it was a big deal when it was announced that The Cannabist has been axed. I mean, it took lot of people surprise because of the work that was coming out of there.

Brad Bogus: Totally. Yeah. It took us by surprise. I mean, if you had asked me prior, I would’ve told you I was the safest person at the Denver Post. I got laid off too.

TG Branfalt: In your opinion, did The Cannabist help break that negative stigma associated with cannabis in Colorado? As you said, The Denver Post came out against Prop 64. A lot of towns and municipalities still don’t allow cannabis operations.

Brad Bogus: Right.

TG Branfalt: Were you guys instrumental in normalizing it in Colorado? You think?

Brad Bogus: I mean, I think so, but it’s impossible to quantify. You know what I mean? In other words, I can say yes, but I can’t really prove it. But the thing about what The Cannabist meant for The Denver Post, at least in and of itself, understanding The Denver Post is like the only existing heartbeat of journalism left in that area, especially after the Rocky Mountain got closed, and the Daily Camera, I think, got folded in. It really just became the Denver Post. So the fact that The Denver Post itself signaled this major change then started to hold …

We would throw a party in The Denver Post building on the week of 420 to kick off the holiday, and we literally would get a cannabis consumption bus to park in the loading dock of The Denver Post.

TG Branfalt: No shit.

Brad Bogus: And our attendees could come and walk through The Denver Post lobby where we would hold the party, to the back loading dock, and we’d have some light foods out there and this consumption bus, and they would go and be able to smoke joints and hit dabs and do a lot of different things there, on the campus of Denver post.

Yeah, right. To know that they were previously against 64, and then that’s where it went, it’s a pretty monumental shift. It’s impossible to say whether that had this major impact on the mainstream culture at large, but it had to, in my opinion. What The Cannabist meant outside of Denver was huge. Our second and third largest audience always came from Texas, and we know that Colorado in and of itself has a ton of cannabis tourism. There’s a ton of those tourists coming from Texas. All of the reach that Cannabist had, even outside of Colorado, help normalize cannabis for Colorado.

Yeah, I think it is really a shame. It’s a sad story when it’s all said and done. But what we experienced within that nine months was so special and wonderful, and we knew its value to its greatest extent while we were there with it. It’s a cherished memory for sure. I don’t think about it negatively other than the fact that it’s just sad to know that it’s not around and still doing what it should be doing.

TG Branfalt: Yeah. Like I said, I mean, I appreciate the work that you guys did. Then to me, knowing what I know, I’m a media studies professor, and I talk about this monopolization, and for me seeing the news that it closed was very sad. But you see this all over the country. But-

Brad Bogus: Yeah, you can’t get too invested with every one of those headlines because you’re just going to be sad, literally every day.

TG Branfalt: Let’s switch gears a little bit. Tell me about Confident Cannabis, what you’re doing over there, about your role. It’s really interesting, and I’m just going to let you blow minds right now.

Brad Bogus: Yeah. Well, it’s a good segue coming out of The Cannabist because what I got at The Cannabist was access to everybody in the industry for the most part. I was able to see a lot of different companies taking different approaches to solve problems in the industry all over the board. I was open to working, coming out of The Cannabist, with any company in the cannabis industry I really believed in, plant-touching or not, it didn’t really matter to me. I just wanted it to be a good company, I wanted to be able to have a material impact at that company, and I wanted to know that they had the right belief system in place, not just for what they were building, but that they were good people.

Corporate social responsibility is important to me. Knowing that there’s a belief system in place with the company that I can actually make the things happen, is why I came into the industry to begin with. So it was important. Anyway, I say all that … preface that to say I was very careful about where I picked my next spot. I had seen a lot of companies come and try to approach the wholesale marketplace, from Tradiv to LeafLink to a couple others that came and flamed out. Then I’ve also seeing a lot of other tech companies try to solve a lot of other problems in the cannabis space.

Ultimately, out of all the companies I evaluated, Confident Cannabis stood out to me as the most valuable approach to trying to solve some of these fundamental business problems, and it was because of the connection to lab testing. To tell you what Confident Cannabis is, at least for the listeners, we’re a software company, we help cannabis businesses test and then buy and sell from one another. The buy and sell part is the wholesale part. But the testing part was a solution we developed because cannabis companies weren’t making wholesale trades happen online for a lot of reasons that technology can’t solve, like distrust or not believing that a thing is what someone says it is, or just not even being able to have a good place that is trustworthy defined products that are only being provided by licensed vendors.

The way to solve that problem isn’t very direct. It’s not easy to figure out, the way we chose to approach it, and ultimately, the piece of the pie that stuck out to me is so interesting, was that the company built laboratory software first, gave it to cannabis labs for almost free or at very low cost depending on what their configuration was. But basically like, “We’re not trying to make money off the lab software. We’re doing this as a means to an end. We’re going to power you with things that you need. Nobody else is providing it to you. And in turn, we’ll be able to get all of this data on all the lab tests that are coming through, and acquire the pipeline of supply that is about to hit the market.”

Because every product has to be tested before it can be bought and sold, a test result essentially represents the earliest a product can be available. It’s like right at the very beginning of the stream, we have a trusted source of information, which is the lab, and we have only licensed producers testing at those labs, giving us their information. What we do with that information, other than obviously protect it and not share it with the world, is we turn that into inventory that we list on our wholesale marketplace once we launched that. We’ve developed another wholesale marketplace. We’ve launched it live in Oregon and in Michigan, and we’ll be launching it in California later this year.

What it does is it takes all of the inventory that you test at a Confident Cannabis partner lab, and immediately shows up in your stock room on wholesale so that buyers can find it and put in order requests for it, and you can start the business of selling to them. All of the test results are linked to all of those products. So the idea that someone doesn’t know what something is and what it tests for, or if they can trust those test results are not photoshopped and not fudged, is all handled by the fact that we have this stream of information coming from the labs.

TG Branfalt: And then you map it, which is the Connect software. To see it in action … I mean, when you were showing me just … we were isolating different compounds based on THC levels, based on terpenes that a lot of people aren’t really aware of, and-

Brad Bogus: Right, right.

TG Branfalt: … going through strain names. You’d have a Blue Dream that’s on one side of the map and then another called Blue Dreams on the other side of the map.

Brad Bogus: Totally.

TG Branfalt: Tell me about that … Try to explain that in a much more precise way than that

Brad Bogus: Totally, totally. Well, all right. Because of our connection to the labs, right? Because of the lab software and the amount of labs that we work with, which is just over half of them nationwide, including Puerto Rico and in British Columbia, we have access to this immense database on cannabis chemistry, arguably the largest in the industry because of those relationships. When you look at cannabis chemistry, at large, across all the products, one thing that has the most question marks in terms of consistency and predictability is flower, right?

When you’re using extracts, you’re producing a pretty consistent outcome, you’re using science to determine a specific proportion of stuff, right? But flower is really quite variable, and the same plant tested over multiple harvests, will have different amounts of things within it. The same plant itself, depending on where you pluck a bud from, will have slight variations in the chemistry based on it’s access to light or water. The fact of the matter is that a lot of decisions are made in the cultivation process of flower, that determine its outcome in cannabis chemistry.

So when we looked at just flower, and we looked specifically at flower that’s been tested for both cannabinoids and terpenes, which the latest research on entourage effects seemed to suggest that those two things together are the best way to really evaluate a predicted effect or flavor or smell of cannabis. So we looked just at flower that had been tested for both cannabinoids and terpenes. What we noticed was the results were very different, even if they had the same strain name genetics, and we wanted to really know why. We also wanted to know what was the overall implication of just being able to see this level of chemistry on flower, and what that could mean for the industry.

So we developed Connect as a way to take all of that data, anonymize it, aggregated across cannabis flower in the whole nation, at least with enough of the states that we have enough test results that we can show statistical significance of it, of which right now I think we’re showing eight recreational states. We took that data and we put it into a 3D environment so that you could play with the universe, rotate, zoom in, zoom out, and really see what the differences in chemistry are within cannabis flower . The fact of the matter is that when you build the data science around this and you place dots that are chemically similar … Dots represent a strain of flower. When you place strains of flower that are chemically similar together, and strains of flower that are chemically dissimilar further apart, the market turns into a shape, right?

And there’s clustering of certain flowers that produce consistent outcomes based on its chemistry, whether it’s CBD dominance, or it has a high amount of terpinolene, which gives you that chemy Pine Sol smell. It’s really present in Durban Poison and Jack Herer. Those things tend to pull certain clusters of cannabis drains away from the others. So what Connect shows you is this shape of the market by its chemistry, which is different than looking at the market by its genetics or looking at it by indica-sativa hybrid, or any of the other ways that we currently categorize flower. The reason we did this was because, when it comes to understanding flower in general as a product, a lot of the things that we use to describe it are either based on inaccurate or incorrect information, or are just our best guesses at things. Right?

So you see indica-sativa hybrid is used on … Maybe 98% of all cannabis is bought and sold based on those two binaries, the indica-sativa binary. But anyone who’s had enough experience using a number of different products across the cannabis spectrum can tell you that they don’t feel just two things from cannabis. They don’t always feel a consistent outcome from indica weed or from sativa weed. What that suggests is that the chemistry is different depending on different outcome, but that indica and sativa probably don’t indicate a really good consistent chemistry.

Connect was our first way of being able to look at cannabis flower by its chemistry, specifically, and say, “Regardless of what the genetics are, and regardless of whether it’s indica or sativa, let’s just see what the chemical outcomes look like,” because it’s the end product that ultimately matters when a customer’s buying it, and being able to predict what they’re going to get is the hardest thing for them when it comes to buying flower. So that’s what Connect represents, and there’s a lot of questions and answers we can dig into a lot more. But the overview is pretty much that.

TG Branfalt: I mean, getting stoned and playing with this 3D map, it’s interesting, it’s fun, right?

Brad Bogus: Yeah.

TG Branfalt: A buddy of mine came over the other day, and he pulls out something, he’s like, “Oh, it’s Purple Kush.” I just look at him, I’m like, “Man, strain names don’t matter.” I brought up Connect and we just start going through it, and his mind is blown. How can Connect fix this problem, or can it fix this problem or help fix this problem with strain names, which vary from state to state, dispensary to dispensary, block to block?

Brad Bogus: Yeah. Yeah. Well, I’d love to say that it’s going to solve the problem, but I don’t think it will. I think it provides a tool to use to solve the problem. But right now the biggest problem we face is that there’s this bridge that needs to be crossed, between what the consumer currently understands about cannabis and what we, with this database, understand about cannabis, or the major educators in this space understand, or even most retailers, right? If you talk to most retailers, they know that indica, sativa doesn’t mean anything. If you talk to most growers, they’ll tell you that too. But they’ll also tell you, “People buy based on this, so this is what we’re doing.”

So there’s got to be a given … It’s a chicken and egg problem, right? Who’s going to lead the consumer to understand what they need to understand, and is it going to be actually knowing what the cannabinoids and terpenes are? Probably not. What this tool can do, however, is armed into the hands of educators and retailers and industry insiders and writers, is provide a basis for which we can start to educate the consumer into understanding what truly matters. There’s still evolution that’s going to occur in the industry here. Some retailers are already getting hip to some of these things, and some cultivators are.

In Oregon especially, I’ve seen the most of this, where they’re deciding to push ahead despite the fact that customer interest seems to show that they only care about high THC numbers. What they’re doing is reforming the way that they fill their shelves. So if you look at Farma in Portland, F-A-R-M-A, or if you look at Serra, S-E-R-R-A, in Portland, these are two different retailers that are leading with the chemistry and they’re showing cannabinoids and terpenes, and helping customers to understand what that means and why they need to know it. But really, I mean, I’m a huge cannabis nerd and I’ve used cannabis a lot. I’ve tested myself across multiple different strains.

What I learned before I even got Connect was that I can use my nose to determine the cannabis I should stay away from and the cannabis I should gravitate towards for multiple different uses. That’s not to say that I just smell it and it makes my brain feel good, because I think a lot of people use the nose knows adage a little bit incorrectly. The nose doesn’t always know. You have to train the knows what to look for, and then the nose becomes a really good chemistry detection tool. So I learned specifically, I should avoid orange smelling strains, even if I like the smell of them, orange geeks me out. But if it’s a berry smell or an earthy funky smell, that will help me be productive.

If I want to get stoned, happy and giggle at really shitty, stupid funny movies, then I’m going to smoke a lemon strain. If I want to enjoy a long walk in the woods, I might focus a little bit more on the spicier strains, the Blackberry Kush, the Blueberry cookies, things like that. I learned that through my own journaling and through smelling every single strain and writing down whether I liked it or not, and what I liked about it. I found consistencies and that’s how I determine how I buy. Then I got Connect, and I was able to learn what it was that my nose was detecting. Right? I can find a bunch of different strains that I’ve tried, I can see what they had in common, I can see what they didn’t have in common, and what I’ve learned is that I actually need to stay away terpinolene as a terpene.

I need to stay away from only limonene-dominant strains as a terpene. But the strains I actually do like, have a combination of limonene myrcene, beta-caryophyllene, a little bit of linalool, a little of alpha beta-Pinene, and CBG, and no THCV. Right? What I was able to do was, as just as a general consumer, journal and figure out what I liked using my nose. Then I taught my nose what it was that it was detecting, and used Connect to unlock what it was I was finding about this stuff. That’s allowed me to realize strain name doesn’t matter anymore, genetics don’t matter anymore. What matters is what is the actual chemistry of that plant. When I go into a dispensary now, I can either tell a really informed bartender, here’s what I’m looking for or I can smell it myself and figure it out already on my own.

So there’s so much discovery that needs to be had here, and there’s so much education that needs to be had here. Connect is the only thing that doesn’t try to make too many assumptions about what all this information means, and just says, “Here’s the information. You’re going to do with it what you will.” The reason why that’s important is because, the other way to address this problem in the industry has been to say, “This is the predicted effect you’re going to have. This is going to make you feel calm. This is going to make you feel enlightened.” But my wife and I feel two totally different things when we smoke the same strain, right?

TG Branfalt: Yeah.

Brad Bogus: What does that mean? That means our brain chemistries are different, or our body’s metabolisms are different, or our response to these compounds is going to be customized based on just what’s going on inside our system. As we know, cannabis is really good at finding homeostasis. But what homeostasis is it going to find? It depends on what you need to balance, right? And that’s going to be different in each person. So I don’t think we can even tell people, “This is what you’re going to feel,” until we start having significant human trials done. So I think that’s a step too far. I think saying indica-sativa matters is not true. So we need to find somewhere in the middle to be. Connect is the tool to help provide information on what that middle looks like. But I personally think it’s going to take people understanding how aroma and chemistry relate to get there.

TG Branfalt: You had mentioned myrcene. Quickly tell me about the … You guys found a link between myrcene, which is a terpene, and Nevada, which is visualized on the map. Explain that that link and why it might matter in some way.

Brad Bogus: Yeah. Well, there’s a lot of things that make weed in Nevada in particular, unique. One of the thing that you’ll notice out in Nevada is that most of the THCV-dominant strains are being produced there. That I don’t know why. Well, actually I can throw a couple of assumptions out there. But specifically myrcene is really interesting in Nevada. One thing to know first and foremost about Nevada is that it’s the only state that requires terpene testing on all products as part of the regulations. So it’s the only state where when you go to buy cannabis flower, whether you want to or not, you’re going to see these chemicals listed, at least the top three or five, listed on the actual package itself.

That, in and of itself, is already a step in the right direction to teaching the consumers what to look for. Nevada cannabis consumers are arguably the most widely educated on terpenes than in any other cannabis consumer for this reason alone, so they know what myrcene is. There was a study that was done, and I think really only one study that shows this, where they took rats, and they gave half the rats phenobarbital, and the other rats phenobarbital with a heavy injection of just myrcene alone, and they found that the rats that got the myrcene injection were slightly more sedated in an exercise than the ones who didn’t. That study has become now the “scientific argument” for myrcene making you higher, or more stoned and more sedate.

When you couple the knowledge of what myrcene is in the state with this supposedly study that people are sharing about myrcene giving you a stonier high, and you’ve got to state that’s already predisposed towards high THC amounts, and just … I mean, it’s Nevada. People like to get faced on whatever it is they’re going to take, right? It makes this perfect little storm. There’s one extra little bit about it, which is that Ed Rosenthal, sometime ago, made up a thing that was like an insider joke, I think. But he made up a story about how if you eat mangoes when you smoke weed, you get higher because mangoes have myrcene in them. Folks ran with that for whatever reason.

So you couple that with these other factors and people in Nevada started to really get hyped on myrcene. A cultivator at the same time realized this was happening, and started to develop extremely myrcene-dominant strains of cannabis called Head Cheese. They won an award, they were published in one of the local mags about winning best strain of Las Vegas or best straight in Nevada, something like that, and they promoted it. Their myrcene content, as an individual terpene content, outpaces overall terpene content in most flower everywhere. Between 4% and 7% of just myrcene alone is what their test results have shown. I’ve got friends who live in Nevada and they constantly keep an eye on this stuff, and they’ll buy new products.

One of them showed me a picture of a product of Head Cheese that had 7% myrcene reported on it. I just couldn’t believe it. But it’s true.

TG Branfalt: That’s off the charts, right?

Brad Bogus: It is astronomical. Astronomical. Yeah. If you see 4% overall terpene content in a flower, that’s a really terpy flower. Most terps show overall content somewhere between say one in 3%, if a producer really cares about terpene content. That’s like the average, right? But an individual terpene is rarely over 1% of the total volume of the terpenes content. So to see one terpene reached 4% to 7% individually, is so far off the charts it’s out of control. There’s a reason that’s happening, and it’s because all of these things have combined into this perfect storm of this thing is super hype in Nevada. I don’t see any other states where a single individual compound receives that much hype outside of just THC, or CBD I guess.

But still, people aren’t buying CBD flower like they are demanding myrcene flower in Nevada. I think the reason why THCV is so popular in Nevada is because there’s this other assumed outcome of THCV that it suppresses appetite. When you think about Las Vegas and being as glamorous as possible, also having a significant amount of female users in Nevada, the idea of having something that doesn’t give you the munchies is pretty appealing. Right? So that’s what they think THCV does. Again, haven’t had enough human trials to confirm any of this stuff, but that’s the common held assumption that that’s what those compounds do, and so they’re both particularly popular there.

TG Branfalt: With all the strains that you see coming in and you map them, what lesser cannabinoids are becoming more popular with cultivators? Is there one that sort of …

Brad Bogus: Yeah. Yeah, it’s a good question. THCV definitely is hitting its come up. Not just in Nevada, but even here in California, there’s a producer called Level, whom has released a number of different products. Some of them that are like tabs, sublingual tabs, that have THCV as the main compound, also CBG. In fact, I think there are couple of cultivators, one at least I know of, in Oregon that are developing CBG-dominant plants, which would be the first time I’ve ever heard of such a thing. CBG is an interesting compound because it does a lot of the same things CBD does. There are a few things it does a little bit differently, but it looks like CBG might actually be a neuroregenerator, which means that it can actually help generate new brain cells, whereas CBD stops the degeneration of brain cells. It doesn’t necessarily regenerate new ones.

TG Branfalt: Interesting.

Brad Bogus: Yeah, so CBG is pretty cool. There still, again, so much more research that needs to be done to confirm most of this stuff. But that’s a minor known cannabinoid. In the extraction process, Delta-8 THC is starting to become really popular. You’re not seeing that in flower, but when … they’ll make distillated Delta-8 now. A number of companies, Guild Extracts in Northern California is one of them. That’s really popular. That’s getting really popular because it’s not so stoney. Supposedly, people report having a half high. Nice, elevated, a little bit higher than a CBD strain, a little bit less high than 20% flower. So that’s pretty interesting. Those are right now what we’re seeing as the major minor cannabinoids that are receiving popularity and being developed in the world.

TG Branfalt: Man, I can sit here and talk to you for another 35 minutes …

Brad Bogus: Yeah, me too, man.

TG Branfalt: I’m definitely going to have a … see when we can link up on this again because there’s so much more to talk about. I mean, we got this list here and we got through three things. Tell me, what advice would you have for entrepreneurs looking to enter this space? You’re an entrepreneur, you’ve been in … I mean, you were at The Cannabist, I mean you’ve filled so many roles, now you’re in a tech … What advice do you have for people who are looking to enter this space?

Brad Bogus: Yeah, I guess it depends on what the entry point’s going to be. So I probably have a little bit-

TG Branfalt: Let’s talk tech.

Brad Bogus: Yeah, if you’re entering the tech space, here’s the biggest thing that turned me off to most tech companies in cannabis, was that they were doing something that already exists everywhere else and just doing the cannabis version of it, whether it’s a loyalty program or a POS or something that’s just been evolved on for decades now, that all it takes is one of those major players just deciding to enter the space and then you just get blown away by them. There’s a lot of companies that are doing that. I find that very uninteresting. The thing that Confident Cannabis did that I found very interesting as a process, and this is the process I would advise for any entrepreneur trying to create anything tech-related in cannabis, is find out what problems you’re trying to solve before you try to create something to solve them.

That requires, before you even say, “This is the thing I want to do,” ask a bunch of people what their biggest problems are. Talk to the cannabis industry that you might be servicing, and find out what their life is like. Don’t assume that you know the problems that they’re facing because they’re general business problems. Don’t assume that you know that what it’s like to be a cultivator because you’ve worked at a cultivation once, right? There’s an understanding here that there’s a lot of variance that occurs in the cannabis industry. Everyone approaches it differently. We haven’t figured out the perfect way to operate in any given state, let alone across the nation, and that’s always going to be evolving.

It’s important to realize that we don’t know everything and we actually don’t know anything, and the only way to know something is to ask a lot of people who actually deal with it, what they’re dealing with. This is a problem that I feel like if everybody took this approach to everything in their life, they’d be a lot better off. You know what I mean? Right? Before you open your mouth, maybe you should talk to people who are dealing with a thing before you give your opinion on it.

TG Branfalt: I just taught a class on Immanuel Kant, and I’m just sitting here like, “Brad Bogus, he’s Immanuel Kant.”

Brad Bogus: Yeah, I never thought I was a Kantian philosopher, but apparently, yeah, if the shoe fits, right? The point is ask questions, learn, humble yourself before people who have done this, and when you really listen, you might find something super interesting that nobody’s really figured out yet. That’s how we did, what we did at Confident Cannabis, was by not just hearing that people need wholesale fixed, but why they don’t do wholesale business. Why don’t cannabis businesses buy from each other online? And the reasons why is not because there wasn’t a place to do it, it’s because of other fundamental reasons that required a special solution to solve that nobody can solve from outside the industry.

That’s why this company interests me so much. But if you’re going to create something new for the industry, don’t try to just create what’s already been done and apply it to the cannabis space. Don’t be a green rusher, right? Really actually care about the industry, care about the producers and their families, care about what innovations they’re creating, be genuinely the most curious you can possibly be, and you’ll find authentic things that you can create that actually will help solve the problem and not just waste money.

TG Branfalt: Well dude, it’s been really great to have you on the show. Like I said, we could keep talking for another 30 minutes, and then we’d have to pull up video and start bouncing around Connect. We would get lost pretty quick. That’s Brad Bogus. He’s the vice president of marketing for Confident Cannabis. He’s apparently an Immanuel Kantian. Thank you so much for being on the Ganjapreneur Podcast, man. I really appreciate it and look forward to talking to you again.

Brad Bogus: Yeah, man. Anytime. I’m looking forward to it as well.

TG Branfalt: You can find more episodes of the Ganjapreneur.com Podcast in the podcast section of Ganjapreneur.com, and in the Apple iTunes Store. On the Ganjapreneur.com website, you’ll find the latest cannabis news and cannabis jobs updated daily along with transcripts of this podcast. You can also download the Ganjapreneur.com app in iTunes and Google Play. This episode was engineered by Trim Media House. I’ve been your host, TG Branfalt.

End


Sweeping Cannabis Legalization Bill Introduced in Pennsylvania

Pennsylvania lawmakers have introduced an adult-use cannabis legalization bill that includes home cultivation, delivery, social-use and expungement, the Philadelphia Inquirer reports. The measure faces an uphill battle in the state – despite support from Gov. Tom Wolf (D) – as Republican members of the House of Representatives have said they have “no plans or interest” in the reforms.

Under the measure, adults would be allowed to cultivate up to 10 plants in their homes for a $50 annual fee and all grows in the state would be capped at 150,000 square feet – an attempt to keep large, corporate, growers from monopolizing the industry. Micro-grow permits – up to 150 plants – would cost $250 annually, compared to $10,000 for large-scale grows, along with a $100,000 application fee.

Bring-Your-Own-Cannabis social-use clubs are permitted under the legislation and could be attached to dispensaries. Those permits carry a $1,000 fee. Delivery service permits ($50) would allow cannabis home delivery by dispensary employees or independent contractors.

The criminal justice reforms in the bill are sweeping: all criminal convictions for what is legal under the law would be expunged, all those incarcerated would receive a commutation, all supervision – probation and parole – for those offenders would cease, and all pending criminal charges would be dismissed. The measure also includes $2 million in interest-free loans for low-income citizens with prior cannabis-related convictions who want to enter the space.

Taxes on cannabis products would be capped at 17.5 percent.

Patrick Nightingale, a Pittsburgh lawyer who support many cannabis causes, called it a “dream bill” but worried it would be blocked by Republican lawmakers.

“Some of them are claiming legalized marijuana causes an increase in homicides and violent crimes, and that it fuels the opioid crisis. If this is going to get passed, we’ll need to have an honest discussion and not mix it in with sky-is-falling and reefer madness rhetoric.” – Nightingale, to the Inquirer

In their September 25 statement, the House Republican Caucus cited the opioid epidemic as a reason not to support adult-use legalization.

“We do not believe easing regulations on illegal drugs is the right move in helping the thousands of Pennsylvanians who are battling drug addiction,” the statement says.

State Sen. Sharif Street (D), one of the sponsors, said he believed the bill “will ultimately be enacted and get wide Republican support.”

End


Two Florida Medical Cannabis Licenses For Sale

Two Florida medical cannabis licenses are for sale totaling $95 million, the Tampa Bay Times reports. One $40 million license allows for up to 30 retail stores, while the other $55 million license allows up to 35 and includes a greenhouse.

The licenses are being brokered by Aubrey Logan-Holland, the CEO of Atlanta, Georgia-based firm Blue Dream Industries.

“Whoever acquires this asset will get a chance to stake their claim in one of the biggest medical markets in the world. It’s a good state to do business.” – Logan-Holland, to the Miami Herald, via the Times

Florida’s medical cannabis industry is vertically integrated, which means the license holders are responsible for growing, processing, testing, and selling medical cannabis products. In all, there are currently 22 licenses in the state but just 13 are active. Licenses in the state have previously sold for as much as $67 million. The two licenses being sold by Blue Dream are inactive and the holders are seeking cash offers.

Jeff Sharkey, lobbyist and director of the state’s Medical Marijuana Business Association, said that, to his knowledge, “all of” the state’s licenses “have been shopped” at some point but “the acquisitions are not as attractive as they were last year.”

“It’s really interesting,” Sharkey told the Times. “Maybe the market has really softened.”

According to the report, there are about 270,000 medical cannabis patients in Florida and Arcview Market research estimates that the state’s industry is expected to generate $1.1 billion in annual revenue by 2022.

End


UK Licenses Canopy Growth for Bulk Medical Cannabis Imports

Canopy Growth’s pharmaceutical division, Spectrum Therapeutics, has been granted a license to import bulk medical cannabis into the United Kingdom, the Financial Times reports. It’s the first such license issued by the Home Office and will allow the company to import cannabis from its facilities in Germany and Denmark and store it in its Buckinghamshire facility.

Paul Steckler, managing director of Canopy’s European business, said the license will allow Canopy to send its medical cannabis products out the next day to UK patients – like it does in Germany. Currently, UK patients can wait up to three months for medical cannabis – which was legalized last November – since wholesalers have needed to wait for an import license from UK officials.

The UK’s medical cannabis program is extremely limited, and it can only be prescribed when all other treatments have failed. Steckler told the Times that the company was “not even looking” at recreational cannabis opportunities in Europe.

“It’s enough of a challenge getting product to patients where it is actually legal.” – Steckler, to the Times

According to the Times, just 1,765 prescriptions have been issued in the UK since legalization last year. Canopy’s Buckinghamshire facility can store enough cannabis to supply 5,000 patients a month.

In June, Spectrum announced they had completed two phase I trials focused on critical dosing and safety data for a proprietary cannabis products which would inform phase II trials. The company also indicated that it had began phase II “proof of concept” trials focused on more than 20 conditions – including sleep, pain, and mood and anxiety disorders – in partnership with researchers at Canada’s Université de Montréal, McGill University, and the Centre for Addiction and Mental Health.

End


CannTrust to Destroy $65M of Cannabis Inventory

CannTrust Holdings Inc. is set to destroy about $65 million worth of inventory and $12 million worth of biological assets that were not authorized by the company’s Health Canada cannabis cultivation license. The assets’ destruction is part of the firm’s remediation plan and necessary in order for the company to get its license back.

Health Canada suspended CannTrust’s license last month after it had found the company had cultivated cannabis in unlicensed rooms at its grow facilities in Vaughan and Pelham, Ontario. Health Canada gave the Vaughan facility a non-compliant rating and ordered CannTrust to propose a remediation plan in August, one month after the company had to place more than 12,000 kilograms of inventory on hold. Danish company StenoCare was forced to quarantine oil derived from cannabis grown at the CannTrust facilities and the fallout led to the ouster of CEO Peter Aceto and the resignation of President Eric Paul.

Robert Marcovitch, who was named Interim CEO in August, said the remediation plan not only addresses the compliance issues outlined by regulators but “will also build a best-in-class compliance environment for the future.”

“We have already made significant progress in these efforts. Our goal is to meet and exceed Health Canada’s regulatory standard, and to rebuild the trust and confidence of our primary regulator, investors, patients, and customers.” – Marcovitch, in a statement

The inventory that will be destroyed includes products returned by patients, distributors, and retailers. The company said it cannot process the material or sell it to another licensed producer because its license suspension only allows it to cultivate plants it had already started growing and it cannot sell or transfer any products.

CannTrust said it will submit a full remediation plan to regulators by October 21.

End


Report: Colorado’s Ebbu Allegedly Violated State Investment Laws

Ebbu, a Colorado-based cannabinoid technology company, is alleged to have misled investors and violated Colorado cannabis investment rules, according to a WeedWeek report based on leaked emails and internal company documents.

Under Colorado‘s adult-use cannabis rules, investors in licensed cannabis companies are supposed to undergo background checks by the state, including fingerprinting and financial disclosures. It appears that Ebbu, however, may have for years promoted an illegal “gifting” investment strategy for investors who wish to remain truly anonymous.

In one specific case from 2013, WeedWeek uncovered evidence of a $140,000 investment given to Ebbu co-founder Michael “Dooma” Wendschuh by an individual only characterized as “E.” One week later, Dooma invested $140,000 into the company without mentioning “E.” According to leaked emails from two months later, the company’s lawyer Christian Sederberg — who co-founded cannabis law firm Vicente Sederberg — was unwilling to participate in similarly structured investment deals.

Ebbu, founded in 2013, was first known for its plan to release a “Feelings” line of cannabis products, which would have each elicited specific sensations/effects such as Energy, Chill, Bliss, etc. The idea has been shared by other cannabis companies, but no company to date has been able to successfully follow through on such effect-specific products. Ebbu has since pivoted to cannabinoid research and was acquired last year by Canadian powerhouse Canopy Growth for approximately $250 million, where Ebbu is focusing on hemp genetics.

WeedWeek said Ebbu executives did not respond to statement requests for their story; Ebbu likewise did not immediately respond to Ganjapreneur’s request for a comment regarding the investment allegations.

End


Denver’s Bonsai Cultivation Issues Flower Product Recall

Denver cannabis company Bonsai Cultivation has issued a recall of its flower, shake, trim, and pre-roll products due to excessively high yeast and mold counts, Denverite reports. The Denver Department of Public Health & Environment says stores and consumers should throw the products away.

“DDPHE opened an investigation after identifying multiple samples of marijuana plant material had failed total yeast and mold sampling from multiple retail store locations. DDPHE is investigating this issue and overseeing the recall process to remove potentially contaminated products from commercial circulation.” – DDPHE, in a statement, via Denverite

At least 45 retail stores, cultivation facilities, and manufacturing facilities throughout Denver are affected by the recall. Products bought between Apr. 30 and Oct. 14 could be affected.

It’s the third recall by Denver cannabis companies this year. In April, Lightshade Labs LLC issued a voluntary recall over yeast and mold which affected flower, shake, trim, and pre-rolls. DDPHE said that investigation was opened following consumer complaints. Affected Lightshade products were sold at five Denver retailers, one Federal Heights retailer, and two Aurora retailers.

In July, Universal Herbs LLC voluntarily recalled pre-rolls of Blue Cookie strains sold at the company’s Denver location over yeast and mold counts.

There have been no confirmed illnesses associated with any of the recalled products but the agency said that potential health impacts depend on the product, duration and frequency of use, and level of exposure.

End


California Gives $3M to UC San Diego for CBD Research

California is giving the University of California, San Diego $3 million to study CBD, the San Diego Union-Tribune reports. The funds will be split between five research projects aimed at exploring the efficacy of CBD to treat psychosis, rheumatoid arthritis, insomnia, alcohol dependence, and anorexia nervosa.

The studies are being conducted by UCSD’s Center for Medicinal Cannabis, which is already studying CBD treatment for children with severe autism.

The funds for the five research projects were taken from cannabis taxes derived from legal sales at licensed dispensaries. The autism study is funded with a $4.7 million grant from the Ray and Tye Noorda Foundation of Lindon, Utah. That gift is still the largest private donation for medical cannabis research in the U.S.

“Within the medical community, there is a lot of interest in the role of medical cannabis and CBD. There is a hope that it could be yet another useful agent in some of these conditions, which are difficult to treat or disabling.” – Igor Grant, director of the UCSD cannabis center, in a statement, via the Union-Tribune

UCSD researchers have been studying medical cannabis since 2000 and has published two studies. In 2007, the center reported that smoked cannabis was effective in treating neuropathic pain; that study was published in the journal Anesthesiology. In 2012, a clinical study at the center found smoked cannabis reduced some symptoms of multiple sclerosis. That study was published in the Canadian Medical Association journal. ‘

The department currently has three cannabis-related clinical trials in progress including the effect of cannabis and endocannabinoids on HIV neuropathic pain, and the effect of vaporized cannabis on neuropathic lower back pain, and one to evaluate the effects of driving under the influence of cannabis.

End


California Gov. Approves Cannabis Tax Overhauls

California Gov. Gavin Newsome (D) signed a bill into law on Saturday that will override the infamous Section 280E of the Internal Revenue Code, which has blocked cannabis businesses from taking advantage of the usual tax deductions afforded to other American businesses, Tom Angell reports for Forbes.

Despite the growing hype around the industry, cannabis businesses nationwide have long struggled to break even or stay afloat due to Section 280E. AB-37, proposed by Assemblymember Reggie Jones-Sawyer (D-Los Angeles), would relieve a significant amount of that pressure for California cannabis companies.

“This bill, for each taxable year beginning on or after January 1, 2020, and before January 1, 2025, would specifically provide in the Personal Income Tax Law for nonconformity to that federal law disallowing a deduction or credit for business expenses of a trade or business whose activities consist of trafficking specified controlled substances only for commercial cannabis activity…” — Excerpt from AB-37

AB-37 was approved alongside many other cannabis-related bills, including one bill instructing officials to create and submit an industrial hemp program satisfying the USDA’s requirements and another bill implementing cannabis compassion programs to benefit low-income medical cannabis patients.

The governor, however, chose to veto legislation that would have allowed the use of medical cannabis products in hospitals, saying the bill departed too far from federal laws and would risk losing federal Medicare and Medicaid funding. “It is inconceivable that the federal government continues to regard cannabis as having no medicinal value,” said Newsom.

End


Dietary Supplement Industry Calls for CBD Protections

Four U.S. dietary supplement trade associations have signed and delivered an open letter to Congress calling for clarification on CBD product marketing and sales, according to a press release.

The groups — the American Herbal Products Association (AHPA), Consumer Healthcare Products Association (CHPA), Council for Responsible Nutrition (CRN), and United Natural Products Alliance (UNPA) — call specifically for Congress to, “pass legislation to clarify that CBD derived from the hemp plant is a lawful dietary ingredient if the dietary supplement containing the CBD meets established product safety and quality criteria.”

“These actions are urgent given the strong consumer interest in CBD, the growth in products and sales, and the need for clarity among consumers, retailers, and manufacturers about the legal status of these products,” the letter reads.

“While FDA has been working to craft its policy on hemp-derived products…it could take three to five years for even an expedited rule-making process to establish a legal regulatory pathway for use of CBD in dietary supplements and conventional foods. Given the rapidly growing marketplace of products…it is crucial that Congress take quick action to clarify the legal status of hemp-derived CBD dietary supplements…[and]…essential for FDA to have the resources it needs to protect the public from unsafe CBD products.” — Excerpt from the letter

Hemp was legalized at the federal level last December and, while the FDA has been working since toward the release of new CBD regulations, the industry remains in a somewhat limbo state with CBD awareness and demand only continuing to rise among consumers.

End


Oregon Enacts 6-Month Flavored Vape Ban

Oregon authorities established new rules on Friday that follow up on an executive order issued by Democratic Gov. Kate Brown on October 4, which called for a statewide ban on flavored nicotine and cannabis vaporizer products, Marijuana Business Daily reports. The ban will take effect starting tomorrow, October 15.

According to Oregon health officials, five of the nine individuals who have fallen ill with the vape-linked pulmonary disease in Oregon had purchased THC vape products from the legal cannabis industry; two of the nine affected patients have died.

Retailers who continue to sell the banned products will receive a written warning and recommendations for becoming compliant before facing civil penalties of up to $500 per day. Cannabis retailers who fail to honor the ban will also run the risk of losing their license, according to Steve Marks, executive director of the Oregon Liquor and Cannabis Commission (OLCC).

Starting October 15, the OLCC will also gain the new ability to require cannabis licensees to send specific product samples over to regulators for testing.

Oregon is the third state to issue a vaporizer ban; Washington recently established a 120-day temporary ban on flavored vaporizer products, while Massachusetts last month approved a more sweeping, four-month ban on all THC and nicotine vape products. Regulators in Colorado, meanwhile, recently proposed stricter rules for THC vape products.

The CDC has released data suggesting that the majority of patients affected by the national, vape-linked pulmonary disease used counterfeit or unregulated cannabis vaporizer products.

End


California Gov. Signs Bill Allowing Medical Cannabis in K-12 Schools

California Gov. Gavin Newsom (D) has signed a bill allowing K-12 students to use medical cannabis at school, the Los Angeles Times reports. The law allows parents in some school districts to bring medical cannabis products to their children at the campus but does not allow those products to be in smokable or vapeable form.

A similar measure was vetoed by former Republican Gov. Jerry Brown in 2018. Under the previous state laws, students or parents could not bring medical cannabis within 1,000 feet of campus and parents had to pick up their child to administer medical cannabis and bring them back.

Los Angeles Unified School District board member Jackie Goldberg told the Times that she believes medical cannabis “ought to be available as a need if the student’s family gets a prescription or a recommendation from a medical doctor.” She indicated the board would ask the district’s health officials for possible policy recommendations.

The measure was opposed by anti-cannabis groups and the California Police Chiefs Association. Scott Chipman, of the group Americans Against Legalizing Marijuana, called the bill a “stunt” and said there was “absolutely no reason” students couldn’t use medical cannabis outside of school hours, adding that the Food and Drug Administration has approved an epilepsy drug that is taken in the morning and evening.

The police chiefs association opposed the law as they seek “to prevent any youth under the age of 21 from accessing all types of cannabis products.”

“While we understand some parents may choose to treat their student’s illnesses with cannabis, we are opposed to allowing parents or guardians administer the drug to their student while on school grounds.” – California Police Chiefs Association, in a statement, to the Times

Sen. Jerry Hill (D), the bill’s sponsor, said the bill is for students “for whom medicinal cannabis is the only medication that works.” He said it would prevent patients from disrupting their studies or those of their classmates.

End


Washington Regulators Ban Flavored Vape Products

The Washington State Board of Health took action on October 10 following an executive order by Gov. Jay Inslee (D), issuing emergency rules banning all flavored vaping products in the state. The rules come on the heels of a nationwide outbreak of vaping related pulmonary disease.

According to the CDC, there have been 1299 vaping related illnesses and 26 vaping-related deaths across the country. The Washington ban covers both nicotine and THC flavored vaped products. The current ban lasts one hundred and twenty days, but the Governor is asking the legislature and the Board to work together to write legislation to permanently ban the sale of flavored vaping products.

In a letter to the Board of Health, The Cannabis Alliance, Washington’s largest cannabis trade organization, said it supported the governor’s efforts to address the teen vaping epidemic.

“The lack of regulation on the nicotine vapor industry and the high use of synthetic and artificial flavors in e-juice products have attracted youth to these products in staggering numbers,” Alliance members wrote. “It’s also clear that the illicit and unregulated cannabis marketplace has no oversight or transparency into the products that our youth and others are accessing on the street.”

The Alliance clarified, however:

The majority of products in the regulated cannabis industry do not utilize strong “youth targeting” flavors. The regulated cannabis industry has a very high youth-access compliance rate (~95%); higher than alcohol by a significant percentage. The regulated cannabis industry is committed to being transparent about their products, the process of making them, and what goes into them. The regulated cannabis industry is committed to working with the state to keep people from seeking products in the unregulated market.” — Excerpt from Cannabis Alliance letter to Washington Board of Health

Additionally, The Washington State Liquor and Cannabis Board has asked all regulated licensees to display signage explaining the ban, disclose all ingredients used to manufacture vaping products, and cooperate with the ongoing “epidemiological investigation” into the cause of the vaping crisis.

End


Texas Shuts Down Dispensary Application Website

The Texas Department of Pubic Safety has abruptly suspended the medical cannabis application process without an explanation just one week after it had opened it up, the Texas Tribune reports. The agency had indicated it would accept applications from Oct. 1 through Nov. 1.

“The Department’s Compassionate Use Program is not accepting applications at this time,” the department’s website says.

“The department will continue to assess dispensing capacity requirements, along with the need for any additional licenses, as we work through recent legislative changes to the program.” – A DPS spokesperson, in an email to the Tribune

In 2017, just three companies were approved to dispense medical cannabis in the state out of 43 that applied. Only Surterra Texas, Cansortium Texas, and Compassionate Cultivation were approved by DPS in the first application round two years ago.

Jax Finkel, executive director of Texas NORML, said it was a “concerning” move by the agency, and that doctors, patients, and the general public were given “no notice and no clear communication.”

State Rep. Stephanie Klick (R), who sponsored the measure to expand the state’s medical cannabis law last session, said the delay was “temporary.”

“Hang tight for now,” Klick told the Tribune. “This is likely just a temporary delay until we know which of the incurable neurodegenerative conditions are appropriate to be included on the list.”

Klick said that officials are trying to determine new patient count estimates after the state added incurable neurodegenerative diseases to the qualifying condition list, which she said could take months.

In May, lawmakers added seizure disorders, multiple sclerosis, spasticity, amyotrophic lateral sclerosis (Lou Gehrig’s Disease), autism, terminal cancer, and incurable neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s diseases to the state’s medical cannabis program.

End


Quebec to Appeal Home Grown Cannabis Ruling

The Quebec government will appeal a September court decision that ruled the province’s ban on home cannabis cultivation is unconstitutional, the Canadian Press reports. Last month, Superior Court Justice Manon Lavoie ruled that the ban equals criminal legislation, which is under federal jurisdiction.

Under Canadian federal law, citizens are allowed to grow up to four plants in their home but Quebec ultimately banned home cultivation under provincial regulations.

Following the ruling, Julien Fortier, the attorney who brought the case, called it a “very technical” decision and warned that the government could bring an appeal or try to rewrite the law in a constitutional way.

Quebec Premier Francois Legault told Airdrie Today that the government “will go right to the limit in the courts to do what we think is good for Quebecers.” He added that both major provincial parties – Coalition Avenir Quebec and Liberals – agree on the ban.

Lionel Carmant, Quebec’s junior health minister, said the province’s stance is different than the rest of the nation and officials support a public health approach to cannabis use and avoid trivializing cannabis use. He added that property owners “think it would be bad for their apartment rentals to permit the growing of cannabis in the home.”

Manitoba has also banned home cannabis cultivation.

Among Canadian provinces, Quebec has taken a conservative approach to cannabis policy and legalization. In July, the government announced a ban on THC-infused candies and confections and capped edible potency at 5 milligrams of THC per unit and 10 milligrams of THC per package; drinkable products are capped at 5 milligrams per container and cannabis-infused topicals will also be banned temporarily. The government is also planning on raising the legal age to purchase and consume cannabis from 18 to 21-years-old.

End


American Trucking Associations Propose Policies for Legal Cannabis

The American Trucking Associations is endorsing policies to help the industry operate while states legalize cannabis for medical and recreational purposes. The trade association is calling on the government to continue allowing for cannabis testing for employees and roadside tests for drivers, in addition to lifting federal restrictions on cannabis research, and the creation of a “marijuana victim’s compensation fund.”

The ATA says that loosening federal restrictions on research would allow for studies that focus on the impact of cannabis-impaired driving.

“ATA has long been an advocate for reducing impaired driving – in all its forms – so it only makes sense that we would call upon state and federal governments to consider the impact of increased use of marijuana on our roadways.” — ATA President and CEO Chris Spear, in a press release

The compensation fund would be paid for by cannabis industry operators, such as dispensaries, cultivators, and manufacturers. 

According to a Transport Topics report, the policies were developed by the ATA’s Controlled Substances, Driver Health and Wellness Subcommittee. The ATA has previously called on the government to allow alternative drug testing methods, backing the creation of a national database for positive alcohol and drug test results, and strengthened anti-impaired driving laws.

“This policy allows us to, while recognizing that the modern world is changing, advocate for strong, safety-oriented policies backed by sound science and data,” Spear said in a statement.

According to the ATA, more than 93 million Americans live in a place with legal adult-use cannabis.

End


Oklahoma Approves 200,000 Medical Cannabis Applications

Oklahoma officials have approved medical cannabis applications for at least 200,000 patients, according to a KFOR report. It’s an average of 3,500 approved applications per week since the Oklahoma Medical Marijuana Authority began accepting applications last year.

Under state law, patients must pay $100 to obtain the license once their application is approved.

Last month, new rules for medical cannabis took effect in the state including seed-to-sale tracking requirements, rules prohibiting physicians from making recommendations in a dispensary, preventing municipalities from barring medical cannabis businesses, and language explicitly allowing medical cannabis patients to possess firearms.

The firearm provision was included due to federal law prohibiting those who buy firearms from using “illegal drugs” — a question asked on federal gun background check forms.

The law also allows employers to consider a patient’s status if they work in “safety sensitive” positions such as firefighting, heavy machinery operation, or handling hazardous materials.   

The rules also require product testing; however, the state has yet to open up applications for testing laboratories. 

Last year, police in Adair County arrested a registered medical cannabis patient. According to a News9 report, that charge was ultimately dismissed.

End